Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 29.59 Million USD | 60.94% |
| 2022 | 18.39 Million USD | -10.77% |
| 2021 | 20.61 Million USD | -11.04% |
| 2020 | 23.16 Million USD | 1.82% |
| 2019 | 22.75 Million USD | 1629.53% |
| 2018 | 1.31 Million USD | 923.74% |
| 2017 | 128.5 Thousand USD | 51.0% |
| 2016 | 85.1 Thousand USD | -14.99% |
| 2015 | 100.1 Thousand USD | -25.91% |
| 2014 | 135.1 Thousand USD | 3.21% |
| 2013 | 130.9 Thousand USD | 13.83% |
| 2012 | 115 Thousand USD | -84.58% |
| 2011 | 745.9 Thousand USD | 16.82% |
| 2010 | 638.5 Thousand USD | -8.8% |
| 2009 | 700.1 Thousand USD | -9.49% |
| 2008 | 773.5 Thousand USD | 224.45% |
| 2007 | 238.4 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 6796.00 USD | -13.91% |
| 2002 | 7894.00 USD | -4.63% |
| 2001 | 8277.00 USD | -41.94% |
| 2000 | 14.25 Thousand USD | -28.72% |
| 1999 | 20 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.5 Million USD | -64.54% |
| 2024 Q2 | 5.37 Million USD | 114.57% |
| 2023 Q4 | 7.06 Million USD | 40.83% |
| 2023 Q2 | 10.75 Million USD | 59.32% |
| 2023 Q1 | 6.75 Million USD | 13.88% |
| 2023 FY | 29.59 Million USD | 60.94% |
| 2023 Q3 | 5.01 Million USD | -53.36% |
| 2022 Q3 | 4.93 Million USD | 15.21% |
| 2022 Q4 | 5.93 Million USD | 20.06% |
| 2022 FY | 18.39 Million USD | -10.77% |
| 2022 Q1 | 3.23 Million USD | 7.09% |
| 2022 Q2 | 4.28 Million USD | 32.56% |
| 2021 Q3 | 5.76 Million USD | -11.14% |
| 2021 Q2 | 6.48 Million USD | 21.63% |
| 2021 Q1 | 5.33 Million USD | -14.67% |
| 2021 FY | 20.61 Million USD | -11.04% |
| 2021 Q4 | 3.02 Million USD | -47.62% |
| 2020 Q2 | 4.36 Million USD | -37.3% |
| 2020 Q1 | 6.95 Million USD | 26.62% |
| 2020 Q3 | 5.6 Million USD | 28.46% |
| 2020 Q4 | 6.25 Million USD | 11.62% |
| 2020 FY | 23.16 Million USD | 1.82% |
| 2019 FY | 22.75 Million USD | 1629.53% |
| 2019 Q2 | 527 Thousand USD | 14.54% |
| 2019 Q3 | 6.08 Million USD | 1054.46% |
| 2019 Q1 | 460.1 Thousand USD | 18.86% |
| 2019 Q4 | 5.49 Million USD | -9.73% |
| 2018 Q4 | 387.1 Thousand USD | 13.22% |
| 2018 Q2 | 391.7 Thousand USD | -14.83% |
| 2018 Q1 | 459.9 Thousand USD | 276.97% |
| 2018 Q3 | 341.9 Thousand USD | -12.71% |
| 2018 FY | 1.31 Million USD | 923.74% |
| 2017 Q3 | 34 Thousand USD | -15.84% |
| 2017 Q1 | 31.9 Thousand USD | 43.69% |
| 2017 Q2 | 40.4 Thousand USD | 26.65% |
| 2017 Q4 | 122 Thousand USD | 258.82% |
| 2017 FY | 128.5 Thousand USD | 51.0% |
| 2016 Q1 | 20.7 Thousand USD | -16.19% |
| 2016 Q4 | 22.2 Thousand USD | 19.35% |
| 2016 Q3 | 18.6 Thousand USD | -11.85% |
| 2016 FY | 85.1 Thousand USD | -14.99% |
| 2016 Q2 | 21.1 Thousand USD | 1.93% |
| 2015 Q3 | 25.5 Thousand USD | -17.74% |
| 2015 Q1 | 20.9 Thousand USD | -7.93% |
| 2015 FY | 100.1 Thousand USD | -25.91% |
| 2015 Q4 | 24.7 Thousand USD | -3.14% |
| 2015 Q2 | 31 Thousand USD | 48.33% |
| 2014 FY | 135.1 Thousand USD | 3.21% |
| 2014 Q3 | 24.7 Thousand USD | -5.36% |
| 2014 Q4 | 22.7 Thousand USD | -8.1% |
| 2014 Q1 | 39.3 Thousand USD | -12.67% |
| 2014 Q2 | 26.1 Thousand USD | -33.59% |
| 2013 Q1 | 29.2 Thousand USD | 3.55% |
| 2013 FY | 130.9 Thousand USD | 13.83% |
| 2013 Q3 | 47.6 Thousand USD | 83.78% |
| 2013 Q4 | 45 Thousand USD | -5.46% |
| 2013 Q2 | 25.9 Thousand USD | -11.3% |
| 2012 Q4 | 28.2 Thousand USD | 105.95% |
| 2012 Q2 | 190.8 Thousand USD | -10.88% |
| 2012 FY | 115 Thousand USD | -84.58% |
| 2012 Q1 | 214.1 Thousand USD | 16.17% |
| 2012 Q3 | -474.1 Thousand USD | -348.48% |
| 2011 Q2 | 197.8 Thousand USD | 3.13% |
| 2011 FY | 745.9 Thousand USD | 16.82% |
| 2011 Q4 | 184.3 Thousand USD | -11.61% |
| 2011 Q1 | 191.8 Thousand USD | 29.68% |
| 2011 Q3 | 208.5 Thousand USD | 5.41% |
| 2010 Q2 | 159.2 Thousand USD | -10.71% |
| 2010 Q1 | 178.3 Thousand USD | 24.25% |
| 2010 FY | 638.5 Thousand USD | -8.8% |
| 2010 Q3 | 157.5 Thousand USD | -1.07% |
| 2010 Q4 | 147.9 Thousand USD | -6.1% |
| 2009 Q3 | 171.9 Thousand USD | 7.17% |
| 2009 Q4 | 143.5 Thousand USD | -16.52% |
| 2009 FY | 700.1 Thousand USD | -9.49% |
| 2009 Q1 | 183.8 Thousand USD | 7.11% |
| 2009 Q2 | 160.4 Thousand USD | -12.73% |
| 2008 Q2 | 232.9 Thousand USD | 7.62% |
| 2008 Q1 | 216.4 Thousand USD | 268.65% |
| 2008 Q4 | 171.6 Thousand USD | -35.37% |
| 2008 FY | 773.5 Thousand USD | 224.45% |
| 2008 Q3 | 265.5 Thousand USD | 14.0% |
| 2007 FY | 238.4 Thousand USD | 0.0% |
| 2007 Q4 | 58.7 Thousand USD | -41.3% |
| 2007 Q3 | 100 Thousand USD | 43.27% |
| 2007 Q1 | 112.7 Thousand USD | 0.0% |
| 2007 Q2 | 69.8 Thousand USD | -38.07% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q3 | 69.8 Thousand USD | 64.24% |
| 2006 Q2 | 42.5 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 100.0% |
| 2004 Q4 | -39.5 Thousand USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q1 | - USD | -100.0% |
| 2004 Q3 | - USD | -100.0% |
| 2004 Q2 | 39.5 Thousand USD | 0.0% |
| 2003 FY | 6796.00 USD | -13.91% |
| 2003 Q1 | 2182.00 USD | 72.9% |
| 2003 Q4 | 1864.00 USD | 82.75% |
| 2003 Q3 | 1020.00 USD | -41.07% |
| 2003 Q2 | 1731.00 USD | -20.67% |
| 2002 Q1 | 3073.00 USD | -1.73% |
| 2002 FY | 7894.00 USD | -4.63% |
| 2002 Q4 | 1262.00 USD | -24.43% |
| 2002 Q3 | 1670.00 USD | -11.55% |
| 2002 Q2 | 1888.00 USD | -38.56% |
| 2001 Q2 | 2208.00 USD | 4.05% |
| 2001 FY | 8277.00 USD | -41.94% |
| 2001 Q1 | 2122.00 USD | 0.0% |
| 2001 Q4 | 3127.00 USD | 281.34% |
| 2001 Q3 | 820.00 USD | -62.86% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | 14.25 Thousand USD | -28.72% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | 20 Thousand USD | 0.0% |
| 1999 Q4 | 10 Thousand USD | 0.0% |
| 1999 Q3 | - USD | -100.0% |
| 1999 Q2 | 10 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -38985.363% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -62.46% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 75.928% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1431.936% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -87.643% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -167864.361% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -37.801% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -44929.516% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -401.474% |
| Marizyme, Inc. | 645.81 Thousand USD | -4482.927% |
| Genus plc | 668.8 Million USD | 95.575% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 87.935% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -29797.772% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -7115.877% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -38457.34% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -74794.985% |
| MultiCell Technologies, Inc. | 49.32 USD | -60010037.875% |
| ONE Bio Corp. | 52.29 Million USD | 43.405% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 40.474% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -60425.562% |
| Q BioMed Inc. | 284.35 Thousand USD | -10308.578% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 79.602% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -5206.88% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -42181.429% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -4394.609% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.799% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -2962562.663% |
| Enzolytics Inc. | 52.79 Thousand USD | -55959.171% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -4763.728% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 97.587% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -21004.234% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4693.937% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 96.475% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -2866.446% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 38.791% |
| BioStem Technologies, Inc. | 16.68 Million USD | -77.383% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -12411.414% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -12411.414% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -2061.943% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -6147.652% |
| SYBLEU INC | 11.69 Thousand USD | -252952.326% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -279.985% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -227569.231% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -74764.673% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -788.799% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -344.066% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -2748.604% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -14.864% |
| CSL Limited | 14.8 Billion USD | 99.8% |
| Cellectis S.A. | 755 Thousand USD | -3820.132% |